The epigenome of testicular germ cell tumors

被引:52
作者
Lind, Guro E. [1 ]
Skotheim, Rolf I.
Lothe, Ragnhild A.
机构
[1] Univ Oslo, Rikshosp, Radium Hosp, Inst Canc Res,Med Ctr,Dept Canc Prevent, N-0027 Oslo, Norway
[2] Univ Oslo, Ctr Biomed, N-0316 Oslo, Norway
关键词
cancer/testis associated genes; DNA methylation; embryogenesis; epigenetics; germ cell; tumor; HIC1; imprinting; MGMT; PRSS21; RASSF1A; SCGB3A1; testicular cancer; X chromosome inactivation;
D O I
10.1111/j.1600-0463.2007.apm_660.xml.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gene expression is tightly regulated in normal cells, and epigenetic changes disturbing this regulation are a common mechanism in the development of cancer. Testicular germ cell tumor (TGCT) is the most common malignancy among young males and can be classified into two main histological subgroups: seminomas, which are basically devoid of DNA methylation, and nonseminomas, which in general have methylation levels comparable with other tumor tissues, as shown by restriction landmark genome scanning (RLGS). In general, DNA methylation seems to increase with differentiation, and among the nonseminomas, the pluripotent and undifferentiated embryonal carcinomas harbor the lowest levels of DNA promoter hypermethylation, whereas the well-differentiated teratomas display the highest. In this regard, TGCTs resemble the early embryogenesis. So far, only a limited number of tumor suppressor genes have been shown to be inactivated by DNA promoter hypermethylation in more than a minor percentage of TGCTs, including MGMT, SCGB3A1, RASSF1A, HIC1, and PRSS21. In addition, imprinting defects, DNA hypomethylation of testis/cancer associated genes, and the presence of unmethylated XIST are frequent in TGCTs. Aberrant DNA methylation has the potential to improve current diagnostics by noninvasive testing and might also serve as a prognostic marker for treatment response.
引用
收藏
页码:1147 / 1160
页数:14
相关论文
共 108 条
  • [1] Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling
    Almstrup, K
    Hoei-Hansen, CE
    Wirkner, U
    Blake, J
    Schwager, C
    Ansorge, W
    Nielsen, JE
    Skakkebæk, NE
    Meyts, ERD
    Leffers, H
    [J]. CANCER RESEARCH, 2004, 64 (14) : 4736 - 4743
  • [2] Genome-wide gene expression profiling of testicular carcinoma in situ progression into overt tumours
    Almstrup, K
    Hoei-Hansen, CE
    Nielsen, JE
    Wirkner, U
    Ansorge, W
    Skakkebæk, NE
    Rajpert-De Meyts, E
    Leffers, H
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (10) : 1934 - 1941
  • [3] ANDREWS PW, 1984, LAB INVEST, V50, P147
  • [4] ATKIN NB, 1982, LANCET, V2, P1349
  • [5] Cytosine methylation and the unequal developmental potentials of the oocyte and sperm genomes
    Bestor, TH
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (06) : 1269 - 1273
  • [6] Unmasking a killer:: DNA O6-methylguanine and the cytotoxicity of methylating agents
    Bignami, M
    O'Driscoll, M
    Aquilina, G
    Karran, P
    [J]. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2000, 462 (2-3) : 71 - 82
  • [7] CLINICAL RELEVANCE OF THE I(12P) MARKER CHROMOSOME IN GERM-CELL TUMORS
    BOSL, GJ
    ILSON, DH
    RODRIGUEZ, E
    MOTZER, RJ
    REUTER, VE
    CHAGANTI, RSK
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (05) : 349 - 355
  • [8] Testicular germ-cell cancer
    Bosl, GJ
    Motzer, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) : 242 - 253
  • [9] Dnmt3L and the establishment of maternal genomic imprints
    Bourc'his, D
    Xu, GL
    Lin, CS
    Bollman, B
    Bestor, TH
    [J]. SCIENCE, 2001, 294 (5551) : 2536 - 2539
  • [10] BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049